crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CR crane

Trading 03-20 12:57:56 EDT

170.64

-3.64

-2.09%

High174.85	Low169.88	Vol133.50K
Open172.95	D1 Closing174.28	Amplitude2.85%
Mkt Cap9.83B	Tradable Cap8.32B	Total Shares57.60M
T/O22.82M	T/O Rate0.27%	Tradable Shares48.76M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CR","market":"US","secType":"STK","nameCN":"crane","latestPrice":170.64,"timestamp":1774025822868,"preClose":174.28,"halted":0,"volume":133501,"delay":0,"changeRate":-0.020885930686252094,"floatShares":48764858,"shares":57596887,"eps":6.247815,"marketStatus":"Trading","change":-3.64,"latestTime":"03-20 12:57:56 EDT","open":172.95,"high":174.85,"low":169.88,"amount":22820247.0869,"amplitude":0.028517,"askPrice":170.76,"askSize":106,"bidPrice":170.4,"bidSize":12,"shortable":3,"etf":0,"ttmEps":6.247815,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774036800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":174.28,"dividendRate":0.005391,"preHourTrading":{"tag":"盘前","latestPrice":174.62,"preClose":174.28,"latestTime":"08:09 EDT","volume":4,"amount":695.71,"timestamp":1774008592085,"change":0.34,"changeRate":0.001951,"amplitude":0.011992},"postHourTrading":{"tag":"盘后","latestPrice":174.28,"preClose":174.28,"latestTime":"17:51 EDT","volume":7401,"amount":1289990.76,"timestamp":1773957075531,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.567782,"optionData":{"bulkOrders":[{"symbol":"CR","call":false,"expireDate":1773979200000,"strike":"210.0","timestamp":1773949656434,"price":33.8,"volume":1470,"amount":4968600,"type":"-"},{"symbol":"CR","call":false,"expireDate":1773979200000,"strike":"200.0","timestamp":1773949656434,"price":23.8,"volume":1160,"amount":2760800,"type":"-"}]},"impliedVol":0.4137,"impliedVolPercentile":0.8207},"requestUrl":"/m/hq/s/CR/tweets","defaultTab":"tweets","newsList":[{"id":"2620766332","title":"Press Release: Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620766332","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620766332?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:01","pubTimestamp":1773950460,"startTime":"0","endTime":"0","summary":"-- Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder. cancer  demonstrated a 95% complete response  rate at any time. and a durable 76% CR rate at 12 months, with favorable safety profile. through 2029, including completion of the NDV-01 RESCUE program. \"NDV-01's compelling efficacy, durability, and favorable safety profile, combined with operational ease-of-use are the cornerstone of its differentiated product profile and best-in-class potential,\" said Raj S. Pruthi, MD, Chief Medical Officer-Oncology of Relmada Therapeutics. \"We continue to be encouraged by the high response rates and durable clinical benefit observed through 12 months, including in the BCG-unresponsive population, alongside a favorable safety profile with no >= Grade 3 treatment-related adverse events and no treatment-related discontinuations. Our clinical program builds on the urologic oncology community's comfort with conventional Gem/Doce's efficacy and safety profile with a sustained relea","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2360107671.USD","BK4007","RLMD","CR","BK4161","LU1861217088.USD","LU1861220207.SGD","BK4166","LENZ","LU0106831901.USD","LU1791807156.HKD","BK4139","BK4588","BK4539","LU1668664300.SGD","DFS"],"gpt_icon":0},{"id":"2620225777","title":"Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620225777","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620225777?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:36","pubTimestamp":1773923760,"startTime":"0","endTime":"0","summary":"Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March  19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3259011/0/en/Moleculin-Reports-Full-Year-2025-Financial-Results-and-Confirms-Highly-Anticipated-45-Patient-Interim-Data-Unblinding-in-Pivotal-MIRACLE-Trial-On-Track-for-Mid-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4161"],"gpt_icon":0},{"id":"2619191297","title":"Crane Company publishes 2025 annual report, net sales rise 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619191297","media":"Reuters","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619191297?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:43","pubTimestamp":1773402212,"startTime":"0","endTime":"0","summary":"Crane reported 2025 sales growth in Aerospace and Process Flow, supported by defense demand and a commercial aerospace production ramp-up. The Aerospace and Advanced Technologies segment posted a 12% sales increase and ended the year with backlog of just over USD 1 billion. Process Flow Technologies reported a record segment operating margin of 21% and cited contributions from the Cryoworks and Technifab acquisitions. The company said it completed acquisitions of Druck, Panametrics, and Reuter Stokes from Baker Hughes, and announced the planned acquisition of optek-Danulat. Crane said CEO Max Mitchell plans to hand the CEO role to COO Alex Alcala at the annual shareholder meeting, with Mitchell expected to serve as Executive Chairman during the transition.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL4B2CH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1366192091.USD","LU1084165304.USD","LU0689472784.USD","LU2168564065.EUR","LU1066051811.HKD","LU1066051225.USD","LU0154245673.USD","LU0742534661.SGD","LU0820561818.USD","BK4585","LU0820561909.HKD","LU0640476718.USD","LU1153585028.USD","LU1974910355.USD","LU0157215616.USD","LU1551013342.USD","LU0149725797.USD","LU0820562030.AUD","LU2463526074.USD","BK4588","LU2543165471.USD","BK4566","LU0354030511.USD","LU1066053197.SGD","LU0353189763.USD","LU0943347566.SGD","LU2168563687.JPY","CR","BK4543","IE0002270589.USD","LU2264538146.SGD","BK4501","LU0353189680.USD","LU1261432733.SGD","LU2756315318.SGD","LU1280957306.USD","LU0077335932.USD","LU0251142724.SGD","LU1988902786.USD","GE","LU1066051498.USD","LU0868494617.USD","LU1119994496.HKD","LU2023250843.SGD","BKR","LU0154245756.USD","BK4187","LU1093756168.USD","LU1917777945.USD"],"gpt_icon":0},{"id":"2619195719","title":"Crane Company announces annual stockholders meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2619195719","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619195719?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:32","pubTimestamp":1773397970,"startTime":"0","endTime":"0","summary":"Crane will hold its annual meeting of stockholders on April 27, 2026 in Old Greenwich, Connecticut. Stockholders will vote on the election of nine directors to serve one-year terms until the 2027 annual meeting. The meeting agenda also includes a proposal to ratify Deloitte & Touche as independent auditor for 2026. Stockholders will also cast a non-binding advisory vote on executive compensation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crane Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL7tXm7T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4161"],"gpt_icon":0},{"id":"2618306889","title":"Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618306889","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618306889?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:00","pubTimestamp":1773144000,"startTime":"0","endTime":"0","summary":"Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients Company expects t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/10/3252699/0/en/Protara-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BCG","IFN","BK4161","BK4523","LENZ","CR","BK4139","BK4007","BK4539"],"gpt_icon":0},{"id":"2618640488","title":"Press Release: enGene Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640488","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640488?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054000,"startTime":"0","endTime":"0","summary":"LEGEND pivotal cohort update planned for a spring 2026 medical conference. 12-month complete response data from LEGEND pivotal cohort expected in 2H 2026. Biologics License Application  submission for detalimogene planned for 2H 2026. Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028. enGene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2026, and provided a business update.\"As data from LEGEND's pivotal cohort in high-risk, BCG-unresponsive NMIBC continues to mature, we look forward to providing an update at a spring medical conference,\" said Ron Cooper, President and Chief Executive Officer, enGene. \"On the heels of our successful November follow-on offering, we entered 2026 in a position of financial strength and ready to execute. With RMAT and CDRP designations for detalimogene, we are in active dialogue with the FDA to ensure regulatory ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2746668974.SGD","IE00BHPRN162.USD","CMC","LU1363072403.SGD","BK4135","BK4588","IE00BZ1G4Q59.USD","LU2746668461.USD","IE00B1BXHZ80.USD","HTGC","DDX","LU2237443465.HKD","LU0971096721.USD","BK4161","BK4006","BK4139","BK4022","BCG","BK4232","CR","LU0267386448.USD","LU2237443549.SGD","LABU","BK4585","LU0170899867.USD","LU0882574139.USD","IE00BFXG1179.USD","LU0149725797.USD","LU2237443622.USD","IE00BKVL7J92.USD","R","ENGN","LU2237443895.HKD","LU2237443382.USD","TRAE","LU2237443978.SGD"],"gpt_icon":0},{"id":"2618064029","title":"Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2618064029","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618064029?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054000,"startTime":"0","endTime":"0","summary":"Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time Tolerabil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251681/0/en/Relmada-Therapeutics-Reports-12-Month-Phase-2-Interim-Data-for-NDV-01-in-Non-Muscle-Invasive-Bladder-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4166","BK4585","LU1791807156.HKD","BK4195","BK4161","BK4588","LENZ","LU1861220207.SGD","LU0106831901.USD","DFS","BK4539","LU1861217088.USD","CR","PFS","BCG","BK4135","LU1668664300.SGD","BK4211","BK4139","BK4007","LU2360107671.USD","TRAE"],"gpt_icon":0},{"id":"2617979542","title":"Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2617979542","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617979542?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:30","pubTimestamp":1772713800,"startTime":"0","endTime":"0","summary":"The Company is expected to finalize the Clinical Study Report (CSR) in Q2 2026 to support planned end of Phase 2 (EOP2) meeting with the FDAPHILADELPHIA, March  05, 2026  (GLOBE NEWSWIRE) -- Medicus P","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/05/3250045/0/en/Medicus-Pharma-Reports-Positive-Phase-2-SKNJCT-003-Topline-Data-Observing-73-Clinical-Clearance-and-40-Histological-Clearance-CR-at-Day-57-in-200%CE%BCg-Cohort.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1935043536.SGD","BK4104","LU0882574139.USD","LU1674673691.USD","LU1935042215.USD","LU1935042991.SGD","BK4567","LU2456880835.USD","LU2417539215.USD","BK4161","BCC","LU0149725797.USD","LU1066051498.USD","LU1066053197.SGD","LU0053666078.USD","LU2083900584.USD","LU0157215616.USD","LU1674673428.USD","LU1366192091.USD","LU0170899867.USD","BK4214","MDCX","LU1066051225.USD","LU1778281490.HKD","LU1066051811.HKD","LU0077335932.USD","LU1935042488.USD","LU2237443549.SGD","LU0786609619.USD","LU2420271590.USD","LU2236285917.USD","MNA","LU1718418525.SGD","LU2237443622.USD","LU1366333091.USD","LU2237443382.USD","LU1935043023.USD","APC","LU2237443978.SGD","LU0314104364.USD","CR","LU1496350171.SGD","BK4139","BK4215","CSR"],"gpt_icon":0},{"id":"2614865082","title":"Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2614865082","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614865082?lang=en_us&edition=fundamental","pubTime":"2026-02-28 01:29","pubTimestamp":1772213340,"startTime":"0","endTime":"0","summary":"-- Strong cash position at year-end 2025: $33.3 million . --    Appointed renowned Rolando Gutierrez-Esteinou, M.D.        --    Seven ongoing oncology trials, with six sponsored by. as new CMO for CNS                                      the NCI or top-tier U.S. institutions. --    Preparing protocol resubmission to incorporate FDA         --    Positive data in 1L AML unfit patients presented at. guidance on Phase III PORTICO-2 trial in aggression                       ASH with 100% ORR . in BPD                               --    Positive data in R/R FLT3+ AML presented at ASH; 67%. into additional EU countries                    --    Initiated enrollment in new Phase Ib trial in small. --    Finalizing preparations for new Phase II trial in                   cell lung cancer in combination with ICI and. aggression in autism spectrum disorder as a part of                                  radiotherapy. the IPCEI EU Grant in personalized medicine             --    Continued momentum ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4097","BK4109","LU2463526074.USD","EMA","BK4144","BK4585","BK4590","NCI","ASH","BK4161","BK4581","BK4202","BK4588","HSCT","ORR","BK4561","CR","ET","BK4081","SCD"],"gpt_icon":0},{"id":"2614859948","title":"ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2614859948","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614859948?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:30","pubTimestamp":1772199000,"startTime":"0","endTime":"0","summary":" EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO-GU 2026) PRINCETON, N.J., Feb","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/27/3246510/0/en/ZUSDURI-Achieves-Durable-Complete-Responses-Across-EORTC-Risk-Groups-in-Patients-with-Recurrent-LG-IR-NMIBC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0124384867.USD","BK4161","LU0256863811.USD","CR","IR","LU1978683503.SGD","BK4585","LU0417517546.SGD","SG9999001440.SGD","LU0256863902.USD","BK4588"],"gpt_icon":0},{"id":"2614611859","title":"ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2614611859","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614611859?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:00","pubTimestamp":1772197200,"startTime":"0","endTime":"0","summary":"- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anti","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/27/3246481/0/en/ALX-Oncology-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BD4GTW91.USD","IE00BMG7P819.SGD","LU2463526074.USD","BK4195","BK4080","PFS","BK4566","BK4109","BK4213","CRC","SITC","IE00BMG7P702.HKD","LU0456854461.SGD","BK4161","LU0266512127.USD","BK4231","ALX","BK4211","IE00BMG7P926.USD","IE00BD4GTT62.SGD","ASH","HR","BK4097","BK4144","ADC","IE00BMG7P587.USD","BK4203","ORR","CR","TRP","OS","IE00BD4GTV84.USD","IE00BMG7P694.USD","BK4225"],"gpt_icon":0},{"id":"2614075332","title":"Federal Signal Appoints Rich Maue and Eric Vaillancourt to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2614075332","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614075332?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:00","pubTimestamp":1772139623,"startTime":"0","endTime":"0","summary":"Federal Signal Corporation appointed Richard “Rich” A. Maue and Eric A. Vaillancourt to its board of directors, effective immediately. Maue is the CFO of Crane Company, and Vaillancourt is President and CEO of Enpro Inc.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL85xhvT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z6F94.USD","BK4149","NPO","BK4161","LU2065732104.USD","LU0054578231.USD","FSS","IE0034390439.USD","LU0566484027.USD","CR","LU1559883803.SGD"],"gpt_icon":0},{"id":"2614783070","title":"Crane posts FY 2025 operating profit USD 424.2 million +19.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614783070","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614783070?lang=en_us&edition=fundamental","pubTime":"2026-02-27 03:25","pubTimestamp":1772133940,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crane Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL66MBVw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1119994496.HKD","GE","LU1280957306.USD","BK4566","LU0267386448.USD","BK4161","CR","LU2168564149.EUR","LU2264538146.SGD","LU0640476718.USD","LU1066051811.HKD","BK4187","LU2168563687.JPY","LU0820561818.USD","LU1551013425.SGD","LU0354030438.USD","LU2756315664.SGD","LU1261432733.SGD","LU0353189680.USD","LU1093756168.USD","LU1064131342.USD","LU1093756325.SGD","LU0354030511.USD","LU1066051498.USD","LU1551013342.USD","LU2168564065.EUR","LU0157215616.USD","LU0943347566.SGD","LU0868494617.USD","LU1988902786.USD","LU2543165471.USD","LU2087625088.SGD","LU0820562030.AUD","LU1084165304.USD","LU0353189763.USD","LU1066051225.USD","BK4543","LU0077335932.USD","LU0149725797.USD","LU0689472784.USD","BK4206","LU2756315318.SGD","BK4588","LU1066053197.SGD","LU1366192091.USD","LU1366333091.USD","LU2168564222.USD","BK4501","LU0820561909.HKD"],"gpt_icon":0},{"id":"2614082639","title":"Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2614082639","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614082639?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:59","pubTimestamp":1772024340,"startTime":"0","endTime":"0","summary":"100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade >3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression free","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/25/3244522/0/en/Tempest-Announces-Interim-Results-from-Ongoing-REDEEM-1-Trial-of-TPST-2003-Preparing-for-Potential-U-S-Registrational-Study-in-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4161","IE00B66KJ199.SGD","CAR","BK4187","IE00B7SZL793.SGD","PFS","CRS","IE00B19Z4B17.USD","BK4139","TPST","CR","SLE","EMD","LU2065731478.USD","BK4211","IE0031619046.USD","BK4230","BK4077","BK4022","BK4195","LU0963586101.USD"],"gpt_icon":0},{"id":"2612446666","title":"Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612446666","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612446666?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:20","pubTimestamp":1771420800,"startTime":"0","endTime":"0","summary":"Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failuresFirst 45 subjects treated on trac","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240197/0/en/Moleculin-MIRACLE-Trial-Delivers-40-Preliminary-Blinded-CRc-Rate-n-30.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4161"],"gpt_icon":0},{"id":"2608507813","title":"Crane CEO buys $183.7K in common stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2608507813","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608507813?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:55","pubTimestamp":1770069316,"startTime":"0","endTime":"0","summary":"In a regulatory filing, Crane (CR) disclosed that its CEO Max Mitchell bought 1K shares of common stock on January 30th in a total transaction size...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crane-ceo-buys-183-7k-in-common-stock-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crane-ceo-buys-183-7k-in-common-stock-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CR","BK4161"],"gpt_icon":0},{"id":"2608281874","title":"Crane Company Chairman, President and CEO Max H. Mitchell Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2608281874","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608281874?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:47","pubTimestamp":1770068862,"startTime":"0","endTime":"0","summary":"Max H. Mitchell, Chairman, President, and CEO of Crane Company, has reported the acquisition of common shares of Crane Company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crane Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL3RGCs0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Crane Company Chairman, President and CEO Max H. Mitchell Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CR"],"gpt_icon":0},{"id":"2607054397","title":"Crane Company Names Alex Alcala CEO as Max Mitchell Becomes Executive Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2607054397","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607054397?lang=en_us&edition=fundamental","pubTime":"2026-01-30 05:56","pubTimestamp":1769723804,"startTime":"0","endTime":"0","summary":"Crane Company has announced that Alejandro  Alcala, currently Executive Vice President and Chief Operating Officer, will be appointed as President and Chief Executive Officer effective April 27, 2026. Max Mitchell, the current Chairman, President, and CEO, will transition to the role of Executive Chairman and continue serving on the Board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crane Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL5JDYPx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4161"],"gpt_icon":0},{"id":"2607135058","title":"Crane Is Maintained at Buy by DA Davidson","url":"https://stock-news.laohu8.com/highlight/detail?id=2607135058","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607135058?lang=en_us&edition=fundamental","pubTime":"2026-01-30 02:52","pubTimestamp":1769712720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 29, 2026 13:52 ET (18:52 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4161"],"gpt_icon":0},{"id":"2606622189","title":"Crane Taps Operating Chief as New CEO, Raises Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2606622189","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606622189?lang=en_us&edition=fundamental","pubTime":"2026-01-27 06:00","pubTimestamp":1769464800,"startTime":"0","endTime":"0","summary":"Crane named a new chief executive and increased its dividend by 11%.The industrial products manufacturer said Monday it named Alex Alcala as president and chief executive, effective April 27.Max Mitchell, who has served as chief executive since 2014, will become executive chair.Alcala is currently Crane's chief operating officer. He joined the company in 2013 as president of pumps and systems.Crane also raised its dividend by 11% to 25.5 cents a share, up from 23 cents.The new payout, equal to $1.02 per year, represents an annual yield of 0.49% based on Monday's closing price of $209.77.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Crane Taps Operating Chief as New CEO, Raises Dividend","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.craneco.com","stockEarnings":[{"period":"1week","weight":-0.0283},{"period":"1month","weight":-0.1289},{"period":"3month","weight":-0.068},{"period":"6month","weight":-0.0427},{"period":"1year","weight":0.1252},{"period":"ytd","weight":-0.055}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Crane NXT, Co. focuses on payment and merchandising technologies. It indents to offer electronic equipment and associated software leveraging extensive, and proprietary core capabilities, including payment verification and authentication, as well as automation solutions, field service solutions, remote diagnostics, and productivity enhancing software solutions. The company is based in Stamford, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.543478,"avgChangeRate":0.020828},{"month":2,"riseRate":0.717391,"avgChangeRate":0.036902},{"month":3,"riseRate":0.565217,"avgChangeRate":0.014104},{"month":4,"riseRate":0.608696,"avgChangeRate":0.002531},{"month":5,"riseRate":0.630435,"avgChangeRate":0.008709},{"month":6,"riseRate":0.586957,"avgChangeRate":0.005131},{"month":7,"riseRate":0.586957,"avgChangeRate":0.004401},{"month":8,"riseRate":0.347826,"avgChangeRate":-0.009516},{"month":9,"riseRate":0.369565,"avgChangeRate":-0.022666},{"month":10,"riseRate":0.586957,"avgChangeRate":0.009396},{"month":11,"riseRate":0.543478,"avgChangeRate":0.025826},{"month":12,"riseRate":0.608696,"avgChangeRate":0.018097}],"exchange":"NYSE","name":"crane","nameEN":"crane"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest crane(CR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"crane,CR,crane股票,crane股票老虎,crane股票老虎国际,crane行情,crane股票行情,crane股价,crane股市,crane股票价格,crane股票交易,crane股票购买,crane股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest crane(CR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}